Physician profile
Renick M Smith
NPI 1346238821
$3,617.69
in general payments reported to CMS, 2019-2025
20 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $329 · 2021: $729 · 2022: $792 · 2023: $646 · 2024: $449 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.82 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $426.86 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $331.47 | 2019-2024 | |
| Janssen Biotech, INC. | $267.22 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $230.67 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.08 | 2019-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $83.03 | 2020-2021 | |
| Daiichi Sankyo INC. | $71.24 | 2021-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $62.48 | 2019-2023 | Ocaliva |
| Celgene Corporation | $48.75 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $44.71 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $39.61 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $33.91 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $33.50 | 2021-2024 | Sutab, Suflave |
| Qol Medical, LLC | $29.63 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $25.21 | 2022-2025 | |
| Allergan, INC. | $18.36 | 2020 | |
| Merit Medical Systems INC | $15.59 | 2023 | Endomaxx Stent and Delivery System |
| Merck Sharp & Dohme LLC | $14.68 | 2019 | |
| Endogastric Solutions, INC | $12.87 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.